These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

508 related items for PubMed ID: 18957001

  • 1. Cardiac arrest with pulseless electrical activity associated with methylphenidate in an adolescent with a normal baseline echocardiogram.
    Daly MW, Custer G, McLeay PD.
    Pharmacotherapy; 2008 Nov; 28(11):1408-12. PubMed ID: 18957001
    [Abstract] [Full Text] [Related]

  • 2. A case study in therapeutic hypothermia treatment post-cardiac arrest in a 56-year-old male.
    Nichols R, Zawada E.
    S D Med; 2008 Oct; 61(10):371-3. PubMed ID: 19051755
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, Spencer T.
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [Abstract] [Full Text] [Related]

  • 4. A case of acute cardiomyopathy and pericarditis associated with methylphenidate.
    Dadfarmay S, Dixon J.
    Cardiovasc Toxicol; 2009 Mar; 9(1):49-52. PubMed ID: 19296063
    [Abstract] [Full Text] [Related]

  • 5. Risperidone-to-methylphenidate switch reaction in children: three cases.
    Sabuncuoglu O.
    J Psychopharmacol; 2007 Mar; 21(2):216-9. PubMed ID: 17329303
    [Abstract] [Full Text] [Related]

  • 6. Methylphenidate induction of complex visual hallucinations.
    Halevy A, Shuper A.
    J Child Neurol; 2009 Aug; 24(8):1005-7. PubMed ID: 19502578
    [Abstract] [Full Text] [Related]

  • 7. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA, Pliszka SR.
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [Abstract] [Full Text] [Related]

  • 8. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A.
    Pediatrics; 2007 Dec; 120(6):e1494-501. PubMed ID: 18055666
    [Abstract] [Full Text] [Related]

  • 9. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B, Sopko MA, Ehret MJ, Paulino RE, Goldberg KR, Angstadt K, Bogart GT.
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [Abstract] [Full Text] [Related]

  • 10. The relationship between shocks and survival in out-of-hospital cardiac arrest patients initially found in PEA or asystole.
    Hallstrom A, Rea TD, Mosesso VN, Cobb LA, Anton AR, Van Ottingham L, Sayre MR, Christenson J.
    Resuscitation; 2007 Sep; 74(3):418-26. PubMed ID: 17452069
    [Abstract] [Full Text] [Related]

  • 11. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
    Findling RL, Wigal SB, Bukstein OG, Boellner SW, Abikoff HB, Turnbow JM, Civil R.
    Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143
    [Abstract] [Full Text] [Related]

  • 12. [Medication for ADHD and the risk of cardiovascular mortality].
    Langendijk PN, Wilde AA.
    Ned Tijdschr Geneeskd; 2006 Aug 05; 150(31):1713-4. PubMed ID: 16924941
    [Abstract] [Full Text] [Related]

  • 13. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ, Chou MC, Tzang RF, Hsu YC, Gau SS, Chen SJ, Wu YY, Huang YF, Liang HY, Cheng H.
    Psychiatry Clin Neurosci; 2009 Apr 05; 63(2):167-75. PubMed ID: 19335386
    [Abstract] [Full Text] [Related]

  • 14. Sibutramine-associated QT interval prolongation and cardiac arrest.
    Ernest D, Gershenzon A, Corallo CE, Nagappan R.
    Ann Pharmacother; 2008 Oct 05; 42(10):1514-7. PubMed ID: 18728104
    [Abstract] [Full Text] [Related]

  • 15. No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy.
    Walitza S, Kämpf K, Artamonov N, Romanos M, Gnana Oli R, Wirth S, Warnke A, Gerlach M, Stopper H.
    Toxicol Lett; 2009 Jan 10; 184(1):38-43. PubMed ID: 19015014
    [Abstract] [Full Text] [Related]

  • 16. [Graphomotor functions in children with attention deficit hyperactivity disorder (ADHD)].
    Stasik D, Tucha O, Tucha L, Walitza S, Lange KW.
    Psychiatr Pol; 2009 Jan 10; 43(2):183-92. PubMed ID: 19697788
    [Abstract] [Full Text] [Related]

  • 17. Acute dyskinesia on starting methylphenidate after risperidone withdrawal.
    Hollis CP, Thompson A.
    Pediatr Neurol; 2007 Oct 10; 37(4):287-8. PubMed ID: 17903675
    [Abstract] [Full Text] [Related]

  • 18. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder.
    Hammerness P, Wilens T, Mick E, Spencer T, Doyle R, McCreary M, Becker J, Biederman J.
    J Pediatr; 2009 Jul 10; 155(1):84-9, 89.e1. PubMed ID: 19394037
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic hypothermia after prolonged cardiopulmonary resuscitation for pulseless electrical activity.
    Bartels M, Tjan DH, Reussen EM, van Zanten AR.
    Neth J Med; 2007 Jan 10; 65(1):38-41. PubMed ID: 17293639
    [Abstract] [Full Text] [Related]

  • 20. An analysis of patient adherence to treatment during a 1-year, open-label study of OROS methylphenidate in children with ADHD.
    Faraone SV, Biederman J, Zimmerman B.
    J Atten Disord; 2007 Sep 10; 11(2):157-66. PubMed ID: 17494833
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.